We are live on ! Find out more
ASPX

AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX

Delisted

ASPX was delisted on the 4th of May, 2015.

61 hedge funds and large institutions have $198M invested in AUSPEX PHARMACEUTICALS INC COM STK (DE) in 2014 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

188% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 8

43% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 14

30% more funds holding

Funds holding: 4761 (+14)

27% less capital invested

Capital invested by funds: $271M → $198M (-$73M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
61
Holders Change
+14
Holders Change %
+29.79%
% of All Funds
1.75%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
23
Increased
20
Reduced
14
Closed
8
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$708K -$3.38M -154,571 -83%
SKK
27
Shepherd Kaplan Krochuk
Massachusetts
$565K -$94.3K -4,312 -15%
BIM
28
BlackRock Investment Management
Delaware
$527K +$14.3K +652 +3%
Charles Schwab
29
Charles Schwab
California
$399K +$392K +17,916 New
PP
30
PDT Partners
New York
$399K +$392K +17,931 New
California State Teachers Retirement System (CalSTRS)
31
California State Teachers Retirement System (CalSTRS)
California
$327K +$2.19K +100 +0.7%
TA
32
Teachers Advisors
New York
$266K +$10.2K +466 +4%
BA
33
BlackRock Advisors
Delaware
$237K +$183K +8,370 +371%
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$232K +$228K +10,435 New
NFA
35
Nationwide Fund Advisors
Ohio
$172K +$82.1K +3,754 +95%
TAM
36
Tocqueville Asset Management
New York
$149K +$4.38K +200 +3%
Swiss National Bank
37
Swiss National Bank
Switzerland
$134K +$131K +6,000 New
AIG
38
American International Group
New York
$117K +$115K +5,271 New
AC
39
Amici Capital
New York
$107K +$105K +4,820 New
PAM
40
Paradigm Asset Management
New York
$90.2K +$88.6K +4,050 New
Creative Planning
41
Creative Planning
Kansas
$89K
Bank of America
42
Bank of America
North Carolina
$89K +$87.2K +3,987 New
Barclays
43
Barclays
United Kingdom
$86K +$81K +3,701 +1,682%
Manulife (Manufacturers Life Insurance)
44
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$74K +$72.8K +3,329 New
AllianceBernstein
45
AllianceBernstein
Tennessee
$67K +$65.6K +3,000 New
Citigroup
46
Citigroup
New York
$41K +$7.68K +351 +24%
U
47
UBS
Switzerland
$40K +$23.7K +1,085 +157%
Nomura Holdings
48
Nomura Holdings
Japan
$38K +$37.2K +1,700 New
Deutsche Bank
49
Deutsche Bank
Germany
$29K -$28.3K -1,295 -49%
LTFS
50
Ladenburg Thalmann Financial Services
Florida
$22K +$10.9K +500 +100%

ASPX Hedge Fund Activity: Q2 2014 in Review

61 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in AUSPEX PHARMACEUTICALS INC COM STK (DE) (ASPX) for Q2 2014, worth a combined $198M — down 27% from $271M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new ASPX positions and 8 closed out — a net gain of 15 holders — while 20 added to existing stakes and 14 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $5.23M. The largest seller was Millennium Management, cutting an estimated $5.18M.

  • 61 institutional investors held AUSPEX PHARMACEUTICALS INC COM STK (DE) (ASPX) as of Q2 2014, up from 47 in Q1 2014.
  • Funds reported $198M of AUSPEX PHARMACEUTICALS INC COM STK (DE) stock for Q2 2014, down 27% quarter-over-quarter.
  • 23 funds opened new AUSPEX PHARMACEUTICALS INC COM STK (DE) positions in Q2 2014 and 8 closed out, a net change of +15 holders.
  • The largest AUSPEX PHARMACEUTICALS INC COM STK (DE) buyer in Q2 2014 was JP Morgan Chase, an estimated $5.23M added.
  • The largest AUSPEX PHARMACEUTICALS INC COM STK (DE) seller in Q2 2014 was Millennium Management, an estimated $5.18M sold.

Based on aggregated 13F filings for Q2 2014.